Search clinical trials for: REGN727

Total 69 results

Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Hypercholesterolemia

United States, Canada, Denmark, France, Hungary, Israel, Korea, Republic of, Russian Federation, South Africa, Ukraine
Beijing Tiantan Hospital
Peking University First Hospital; General Hospital of Shenyang Military Region and other collaborators

Completed

Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset (Salfaprodil)

Stroke | Cerebral Infarction

China
University of California, San Francisco
Massachusetts General Hospital

Recruiting

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) (EPIC-HIV)

Cardiovascular Diseases | HIV Infections | Dyslipidemias

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Hypercholesterolemia

France, Belgium, Austria, Canada, Czechia, Denmark, Finland, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland
Regeneron Pharmaceuticals

Recruiting

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

United States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY EAST)

Hypercholesterolemia

China, India, Thailand
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
Regeneron Pharmaceuticals

Not yet recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Melanoma
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Pembrolizumab in Adult Participants With Resectable Stage 3 or 4 Melanoma

Melanoma
Sanofi
Regeneron Pharmaceuticals

Completed

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS)

Hypercholesterolaemia

Norway, Russian Federation, Sweden, South Africa, Czechia, United States, Canada, France, Netherlands, Spain
University of Wisconsin, Madison
Bristol-Myers Squibb; National Cancer Institute (NCI); United States Department... and other collaborators

Recruiting

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Prostate Cancer

United States
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Hypercholesterolemia

Slovenia, Taiwan, Russian Federation, Canada, Netherlands, Brazil, Denmark, Mexico, Spain, Turkey
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Hypercholesterolaemia

Czechia, France, Denmark, Netherlands, Austria, Mexico, Spain, United States, Argentina, Brazil, Bulgaria, Canada, Finland, Hungary, Italy, Lebanon, Norway, Poland, Russian Federation, Slovenia, South Africa, Sweden, Taiwan, Turkey
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Georgia
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-small Cell Lung Cancer That Can be Treated With Surgery.

Resectable Non-small Cell Lung Cancer
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Multiple Myeloma

United States, Spain, France, Greece
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States

Search clinical trials for: REGN727

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations